Publicacions en col·laboració amb investigadors/es de Klinikum der Universität München (11)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

2021

  1. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  2. Survival and quality of life after early discharge in low-risk pulmonary embolism

    European Respiratory Journal, Vol. 57, Núm. 2

2020

  1. ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries

    European Journal of Internal Medicine, Vol. 82, pp. 48-55

  2. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months

    Thrombosis Research, Vol. 196, pp. 297-304

  3. Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: An international multicentre single-arm clinical trial

    European Heart Journal, Vol. 41, Núm. 4, pp. 509-518

2018

  1. Correction: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study [Thrombosis Journal, 16, (2018) (9)] DOI: 10.1186/s12959-018-0163-7

    Thrombosis Journal

  2. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

    Thrombosis Journal, Vol. 16, Núm. 1

2014

  1. Fibrinolysis for patients with intermediate-risk pulmonary embolism

    New England Journal of Medicine, Vol. 370, Núm. 15, pp. 1402-1411